Answers are grounded in this paper and cite their sources.
The safety of maternal codeine use during breastfeeding remains controversial, largely due to debate surrounding the "Toronto Case," in which a neonatal death was associated with elevated morphine exposure following maternal postpartum codeine therapy. Critics have argued that this outcome requires an exceptionally unlikely combination of several factors. This review details the physiological and pharmacokinetic complexities of infant opioid exposure and toxicity in breastfed infants by reexamining assumptions underlying the physiology-based pharmacokinetic (PBPK) model frequently cited to challenge the plausibility of the Toronto Case. When advances in developmental pharmacology, pharmacogenomics, and maternal and neonatal drug disposition that have occurred over the past 15 years are considered, an integrated mother-milk-infant system emerges in which individualized risk assessment can be conceptualized as the convergence of multiple factors, each of which contributes to the overall risk for a given mother-child dyad. Future modeling and simulations must include the maternal and neonatal determinants that predispose specific breastfeeding mother-newborn pairs to excessive sedation and respiratory failure after codeine administration, and generate evidence to support safer opioid therapy in breastfeeding mothers, breastfed infants, and older children.
No takes yet. Share an insight, caveat, or question.
Leeder et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: